Evaluation The Effect Of Magnesium Oxide Supplementation On The Severity Of Clinical Symptoms In Patients With Parkinson's Disease

Evaluation Efficacy And Short-term Safety of Magnesium Oxide Supplementation On The Severity Of Clinical Symptoms InParkinson's Disease: A Randomized Clinical Trial Study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023084N24

Enrollment

Registered

2025-07-09

Start date

2025-07-23

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson. Parkinson's disease

Interventions

Intervention 1: Intervention group: Before the intervention, the serum level of magnesium should be measured in the patients, and only 20 of the patients who have a normal serum level of magnesium, to

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Age greater than or equal to 18 years Informed consent of the patient Having mild to severe Parkinson's symptoms At least 2 years have passed since the onset of the disease The serum level of magnesium is normal (equivalent to about 1.8 to 2.4 mg/dL)

Exclusion criteria

Exclusion criteria: Patient dissatisfaction Taking supplements containing magnesium Non-cooperation in evaluation with questionnaire Not having a good general mood

Design outcomes

Primary

Measure	Time frame
Severity of symptoms in patients with Parkinson's disease. Timepoint: before the start of the intervention and two months after taking the magnesium oxide supplement. Method of measurement: Clinical examinations by a specialist doctor and questions from the patient.;Quality of life of patients based on PDQ39 index. Timepoint: before the start of the intervention and two months after taking the magnesium oxide supplement. Method of measurement: PDQ 39 questionnaire.	—

Measure

Time frame

Severity of symptoms in patients with Parkinson's disease. Timepoint: before the start of the intervention and two months after taking the magnesium oxide supplement. Method of measurement: Clinical examinations by a specialist doctor and questions from the patient.;Quality of life of patients based on PDQ39 index. Timepoint: before the start of the intervention and two months after taking the magnesium oxide supplement. Method of measurement: PDQ 39 questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Shiehmorteza

Islamic Azad University

shiehmorteza@iaups.ac.ir+98 21 2264 0056

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026